Population Pharmacokinetics of Abrocitinib in Healthy Individuals and Patients with Psoriasis or Atopic Dermatitis.

ABSTRACT:

Background and objective

Abrocitinib is a Janus kinase 1 inhibitor in development for the treatment of atopic dermatitis (AD). This work characterized orally administered abrocitinib population pharmacokinetics in healthy individuals, patients with psoriasis, and patients with AD and the effects of covariates on abrocitinib exposure.

Methods

Abrocitinib concentration measurements (n = 6206) from 995 individuals from 11 clinical trials (seven phase I, two phase II, and two phase III) were analyzed, and a non-linear mixed-effects model was developed. Simulations of abrocitinib dose proportionality and steady-state accumulation of maximal plasma drug concentration (C_max) and area under the curve (AUC) were conducted using the final model.

Results

A two-compart

SUBMITTER: Wojciechowski J 

PROVIDER: S-EPMC9095539 | biostudies-literature | 2022 May

REPOSITORIES: biostudies-literature